Page 51 - TD-4-3

Tumor Discovery HRD genomic alterations in Chinese NSCLC

14. Conrad LB, Lin KY, Nandu T, Gibson BA, Lea JS, Kraus WL. identifies clinically relevant vulnerabilities. Nat Commun.
ADP-ribosylation levels and patterns correlate with gene 2022;13(1):514.
expression and clinical outcomes in ovarian cancers. Mol doi: 10.1038/s41467-022-27987-5
Cancer Ther. 2020;19(1):282-291.
25. Marquard AM, Eklund AC, Joshi T, et al. Pan-cancer analysis
doi: 10.1158/1535-7163.MCT-19-0569
of genomic scar signatures associated with homologous
15. Jia Z, Liu Y, Qu S, et al. Evaluative methodology for HRD recombination deficiency suggests novel indications for
testing: Development of standard tools for consistency existing cancer drugs. Biomark Res. 2015;3:9.
assessment. Genomics Proteomics Bioinform. 2025.
doi: 10.1186/s40364-015-0033-4
doi: 10.1093/gpbjnl/qzaf017
26. Rempel E, Kluck K, Beck S, et al. Pan-cancer analysis
16. Makvandi M, Pantel A, Schwartz L, et al. A PET imaging of genomic scar patterns caused by homologous repair
agent for evaluating PARP-1 expression in ovarian cancer. deficiency (HRD). NPJ Precis Oncol. 2022;6(1):36.
J Clin Invest. 2018;128(5):2116-2126.
doi: 10.1038/s41698-022-00276-6
doi: 10.1172/JCI97992
27. Takamatsu S, Brown JB, Yamaguchi K, et al. Utility of
17. Hahnen E, Lederer B, Hauke J, et al. Germline mutation homologous recombination deficiency biomarkers across
status, pathological complete response, and disease-free cancer types. JCO Precis Oncol. 2022;6:e2200085.
survival in triple-negative breast cancer: Secondary analysis doi: 10.1200/PO.22.00085
of the geparsixto randomized clinical trial. JAMA Oncol.
2017;3(10):1378-1385. 28. Hodgson D, Lai Z, Dearden S, et al. Analysis of mutation
status and homologous recombination deficiency in tumors
doi: 10.1001/jamaoncol.2017.1007
of patients with germline BRCA1 or BRCA2 mutations
18. Shang X, Qi K, Liu X, et al. Signatures associated with and metastatic breast cancer: OlympiAD. Ann Oncol.
homologous recombination deficiency and immune 2021;32(12):1582-1589.
regulation to improve clinical outcomes in patients with doi: 10.1016/j.annonc.2021.08.2154
lung adenocarcinoma. Front Oncol. 2022;12:854999.
29. Zhou Z, Ding Z, Yuan J, et al. Homologous recombination
doi: 10.3389/fonc.2022.854999
deficiency (HRD) can predict the therapeutic outcomes of
19. Su R, Liu Y, Wu X, Xiang J, Xi X. Dynamically accumulating immuno-neoadjuvant therapy in NSCLC patients. J Hematol
homologous recombination deficiency score served as an Oncol. 2022;15(1):62.
important prognosis factor in high-grade serous ovarian doi: 10.1186/s13045-022-01283-7
cancer. Front Mol Biosci. 2021;8:762741.
30. González-Martín A, Pothuri B, Vergote I, et al. Niraparib
doi: 10.3389/fmolb.2021.762741
in patients with newly diagnosed advanced ovarian cancer.
20. Qing T, Wang X, Jun T, Ding L, Pusztai L, Huang KL. Genomic N Engl J Med. 2019;381(25):2391-2402.
determinants of homologous recombination deficiency doi: 10.1056/NEJMoa1910962
across human cancers. Cancers (Basel). 2021;13(18):4572.
31. Telli ML, Timms KM, Reid J, et al. Homologous
doi: 10.3390/cancers13184572
recombination deficiency (HRD) score predicts response
21. Bever KM, Le DT. DNA repair defects and implications for to platinum-containing neoadjuvant chemotherapy in
immunotherapy. J Clin Invest. 2018;128(10):4236-4242. patients with triple-negative breast cancer. Clin Cancer Res.
2016;22(15):3764-3773.
doi: 10.1172/JCI122010
doi: 10.1158/1078-0432.CCR-15-2477
22. Ray-Coquard I, Leary A, Pignata S, et al. Olaparib plus
bevacizumab first-line maintenance in ovarian cancer: Final 32. Feng J, Lan Y, Liu F, et al. Combination of genomic instability
overall survival results from the PAOLA-1/ENGOT-ov25 score and TP53 status for prognosis prediction in lung
trial. Ann Oncol. 2023;34(8):681-692. adenocarcinoma. NPJ Precis Oncol. 2023;7(1):110.
doi: 10.1016/j.annonc.2023.05.005 doi: 10.1038/s41698-023-00465-x
23. Yang C, Zhang Z, Tang X, et al. Pan-cancer analysis reveals 33. Moretto R, Elliott A, Zhang J, et al. Homologous
homologous recombination deficiency score as a predictive recombination deficiency alterations in colorectal cancer:
marker for immunotherapy responders. Hum Cell. Clinical, molecular, and prognostic implications. J Natl
2022;35(1):199-213. Cancer Inst. 2022;114(2):271-279.
doi: 10.1007/s13577-021-00630-z doi: 10.1093/jnci/djab169
24. Cosgrove N, Varešlija D, Keelan S, et al. Mapping molecular 34. Khan R, Pari B, Puszynski K. Comprehensive bioinformatic
subtype specific alterations in breast cancer brain metastases investigation of TP53 dysregulation in diverse cancer

Volume 4 Issue 3 (2025) 43 doi: 10.36922/TD025180032